Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.

@article{Atkins1997PhaseIE,
  title={Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.},
  author={Michael B. Atkins and Michael J. Robertson and Michael M. Gordon and Michael T Lotze and M. E. D{\'e}coste and Jon S. Dubois and Jerome Ritz and Alan B. Sandler and Howard D. Edington and Pamela D. Garzone and James Walter Mier and Christine M. Canning and Linda Battiato and Hideki Tahara and Matthew L. Sherman},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={1997},
  volume={3 3},
  pages={409-17}
}
A Phase I dose escalation trial of i.v. administered recombinant human interleukin 12 (rhIL-12) was performed to determine its toxicity, maximum tolerated dose (MTD), pharmacokinetics, and biological and potential antineoplastic effects. Cohorts of four to six patients with advanced cancer, Karnofsky performance >/=70%, and normal organ function received escalating doses (3-1000 ng/kg/day) of rhIL-12 (Genetics Institute, Inc.) by bolus i.v. injection once as an inpatient and then, after a 2… CONTINUE READING
Highly Influential
This paper has highly influenced 10 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS